昂利康(002940.SZ):正和海西聯合藥業就可能開展的七氟烷和地氟烷兩個製劑產品的聯合研發和註冊申報等方面合作事宜進行探討
格隆匯 6 月 17日丨昂利康(002940.SZ)公佈,近日,公司接到投資者的問詢,要求公司説明與福建海西聯合藥業有限公司(“海西聯合藥業”)開展的產品聯合研發和註冊申報的相關內容,為了體現信息公平披露的原則,公司現就相關合作事項公告説明如下:
截至公告披露之日,公司正在和海西聯合藥業就未來可能開展的七氟烷和地氟烷兩個製劑產品的聯合研發和註冊申報等方面的合作事宜進行探討,雙方計劃按照等比例投入、等比例享有上述製劑產品的全部成果和收益的原則確定具體的合作方案和收益分配比例,有關具體合作的方式和內容尚有待於進一步探討。按等比例投入的原則經初步測算,公司在上述產品上計劃投入的研發和註冊申報的金額預計不超過人民幣1000萬元;
截至公告披露之日,雙方尚未就相關合作事項簽署或達成任何實質性的有約束力的協議、承諾或其他安排;
截至公告披露之日,海西聯合藥業的第一大股東為朱吉洪,公司及關聯方未在海西聯合藥業持有任何股權,公司和海西聯合藥業的本次合作內容暫未涉及股權合作方面的具體安排。
公司與海西聯合藥業尚未就相關合作事項簽署或達成任何實質性的有約束力的協議、承諾或其他安排,此次合作的具體事項有待於進一步探討,此次合作存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.